Finance

Lists
BXA0:FRA
Lavipharm SA
€1.52
+0.13%
(+0.0020) 1D
Sep 3, 3:25:02 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for BXA0...
Open
€1.50
High
€1.54
Low
€1.50
Mkt. cap
275.38M
Avg. vol.
1.00
Volume
0.00
Dividend
1.31%
Quarterly dividend
€0.00
Ex-dividend date
Jul 20, 2026
P/E ratio
50.87
52-wk high
€1.85
52-wk low
€0.71
EPS
€0.03
No. of employees
285
Open
€1.50
High
€1.54
Low
€1.50
Mkt. cap
275.38M
Avg. vol.
1.00
Volume
0.00
Dividend
1.31%
Quarterly dividend
€0.00
Ex-dividend date
Jul 20, 2026
P/E ratio
50.87
52-wk high
€1.85
52-wk low
€0.71
EPS
€0.03
No. of employees
285
Profile
Lavipharm S.A. is the largest integrated Greek pharmaceutical company that develops, manufactures, markets and distributes pharmaceutical, cosmetic, veterinary and consumer health products in Greece and internationally. It was founded in 1911, by the Lavidas’ family, and listed on the Athens Stock Exchange in 1995. Wikipedia
About Lavipharm SA
CEO-
Employees285
Founded1911
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Mar 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
12.70M
14.90M
20.97M
14.65M
Cost of goods sold
6.67M
8.54M
9.48M
8.07M
Cost of revenue
6.67M
8.54M
9.48M
8.07M
Research and development expenses
-
-137.00K
344.00K
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-9.76M
22.99M
-
Operating expense
4.47M
6.18M
7.20M
4.75M
Total operating expenses
11.14M
14.71M
16.68M
12.82M
Operating income
1.56M
189.00K
4.29M
1.83M
Other non operating income
-
43.00K
-61.00K
-
EBT including unusual items
1.10M
1.07M
3.17M
1.41M
EBT excluding unusual items
1.10M
1.19M
2.34M
1.41M
Income tax expense
410.00K
190.00K
693.00K
590.00K
Effective tax rate
37.27%
17.74%
21.84%
41.84%
Other operating expenses
4.47M
16.07M
-16.13M
4.75M
Net income
1.63M
884.00K
2.48M
820.00K
Net profit margin
12.83%
5.93%
11.80%
5.60%
Earnings per share
-
-
-
-
Interest and investment income
-
928.00K
56.00K
-
Interest expense
-460.00K
-29.00K
-1.84M
-420.00K
Net interest expenses
-460.00K
899.00K
-1.78M
-420.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
2.52M
1.15M
5.37M
2.90M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps